Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Predicting oligonucleotide therapeutic efficacy at the population level.

Theotokis PI, Usher L, Kortschak CK, Schwalbe E, Moschos SA.

Hell J Nucl Med. 2019 Sep-Dec;22 Suppl 2:182.

2.

Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience.

Karachaliou GS, Ayvali F, Collichio FA, Lee CB, Ivanova A, Ollila DW, Moschos SJ.

Oncology. 2019 Dec 3:1-5. doi: 10.1159/000504578. [Epub ahead of print]

PMID:
31794964
3.

RACE-SEQ and Population-Wide Polymorphism Susceptibility Testing for Endonucleolytically Active, RNA-Targeting Therapeutics.

Usher L, Theotokis PI, Moschos SA.

Methods Mol Biol. 2019;2036:283-305. doi: 10.1007/978-1-4939-9670-4_17.

PMID:
31410804
4.

Measuring the Action of Oligonucleotide Therapeutics in the Lung at the Cell Type-Specific Level by Tissue Disruption and Cell Sorting (TDCS).

Graves H, Evans S, Fauler M, Frick M, Moschos SA.

Methods Mol Biol. 2019;2036:187-203. doi: 10.1007/978-1-4939-9670-4_11.

PMID:
31410798
5.

Prognostic value of B cells in cutaneous melanoma.

Selitsky SR, Mose LE, Smith CC, Chai S, Hoadley KA, Dittmer DP, Moschos SJ, Parker JS, Vincent BG.

Genome Med. 2019 May 28;11(1):36. doi: 10.1186/s13073-019-0647-5.

6.

Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.

Sambade MJ, Prince G, Deal AM, Trembath D, McKee M, Garrett A, Keith K, Ramirez J, Midkiff B, Blackwell K, Sammons S, Leone JP, Brufsky A, Morikawa A, Brogi E, Seidman A, Ewend M, Carey LA, Moschos SJ, Hamilton RL, Vincent B, Anders C.

Breast Cancer Res Treat. 2019 Jul;176(2):321-328. doi: 10.1007/s10549-019-05211-1. Epub 2019 Apr 23.

PMID:
31016641
7.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ.

Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.

8.

Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.

Conway K, Edmiston SN, Parker JS, Kuan PF, Tsai YH, Groben PA, Zedek DC, Scott GA, Parrish EA, Hao H, Pearlstein MV, Frank JS, Carson CC, Wilkerson MD, Zhao X, Slater NA, Moschos SJ, Ollila DW, Thomas NE.

J Invest Dermatol. 2019 Jun;139(6):1349-1361. doi: 10.1016/j.jid.2018.11.024. Epub 2018 Dec 6.

PMID:
30529013
9.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

10.

Extracellular vesicles and their nucleic acids for biomarker discovery.

Momen-Heravi F, Getting SJ, Moschos SA.

Pharmacol Ther. 2018 Dec;192:170-187. doi: 10.1016/j.pharmthera.2018.08.002. Epub 2018 Aug 3. Review.

PMID:
30081050
11.

A novel antifungal property for the Bacillus licheniformis ComX pheromone and its possible role in inter-kingdom cross-talk.

Esmaeilishirazifard E, Dariush A, Moschos SA, Keshavarz T.

Appl Microbiol Biotechnol. 2018 Jun;102(12):5197-5208. doi: 10.1007/s00253-018-9004-7. Epub 2018 Apr 23.

PMID:
29687141
12.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT.

JCI Insight. 2018 Feb 22;3(4). pii: 92352. doi: 10.1172/jci.insight.92352. eCollection 2018 Feb 22.

13.

Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs.

Theotokis PI, Usher L, Kortschak CK, Schwalbe E, Moschos SA.

Mol Ther Nucleic Acids. 2017 Dec 15;9:22-33. doi: 10.1016/j.omtn.2017.08.010. Epub 2017 Aug 24.

14.

Oligonucleotide Therapies for the Lung: Ready to Return to the Clinic?

Kumar M, Moschos SA.

Mol Ther. 2017 Dec 6;25(12):2604-2606. doi: 10.1016/j.ymthe.2017.11.002. Epub 2017 Nov 23. No abstract available.

15.

Field-deployable, quantitative, rapid identification of active Ebola virus infection in unprocessed blood.

Shah K, Bentley E, Tyler A, Richards KSR, Wright E, Easterbrook L, Lee D, Cleaver C, Usher L, Burton JE, Pitman JK, Bruce CB, Edge D, Lee M, Nazareth N, Norwood DA, Moschos SA.

Chem Sci. 2017 Nov 1;8(11):7780-7797. doi: 10.1039/c7sc03281a. Epub 2017 Sep 25.

16.

Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.

Bakhru P, Zhu ML, Wang HH, Hong LK, Khan I, Mouchess M, Gulati AS, Starmer J, Hou Y, Sailer D, Lee S, Zhao F, Kirkwood JM, Moschos S, Fong L, Anderson MS, Su MA.

JCI Insight. 2017 Sep 21;2(18). pii: 93265. doi: 10.1172/jci.insight.93265. eCollection 2017 Sep 21.

17.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV.

Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4.

18.

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.

Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM.

Melanoma Res. 2017 Aug;27(4):342-350. doi: 10.1097/CMR.0000000000000353.

PMID:
28489678
19.

Genomic and molecular characterization of a novel quorum sensing molecule in Bacillus licheniformis.

Esmaeilishirazifard E, De Vizio D, Moschos SA, Keshavarz T.

AMB Express. 2017 Dec;7(1):78. doi: 10.1186/s13568-017-0381-6. Epub 2017 Apr 8.

20.

The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy.

Kaidar-Person O, Zagar TM, Deal A, Moschos SJ, Ewend MG, Sasaki-Adams D, Lee CB, Collichio FA, Fried D, Marks LB, Chera BS.

Anticancer Drugs. 2017 Jul;28(6):669-675. doi: 10.1097/CAD.0000000000000497.

PMID:
28368903
21.
22.

Exceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated With Hyper-Indel-Hypermutated Cancer Genome and Comutation of POLD1 and MLH1.

Sharma MR, Auman JT, Patel NM, Grilley-Olson JE, Zhao X, Moschos SJ, Parker JS, Yin X, Hayward MC, Polite BN, Marangon E, Posocco B, Toffoli G, Hayes DN, Innocenti F.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00015. Epub 2017 Apr 27.

23.

Clinical potential of oligonucleotide-based therapeutics in the respiratory system.

Moschos SA, Usher L, Lindsay MA.

Pharmacol Ther. 2017 Jan;169:83-103. doi: 10.1016/j.pharmthera.2016.10.009. Epub 2016 Oct 19. Review.

PMID:
27771436
24.

Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642. doi: 10.1111/pcmr.12538. Epub 2016 Oct 22. Review.

25.

Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and Melanoma.

Franceschi AM, Moschos SJ, Anders CK, Glaubiger S, Collichio FA, Lee CB, Castillo M, Lee YZ.

J Comput Assist Tomogr. 2016 Sep-Oct;40(5):803-5. doi: 10.1097/RCT.0000000000000420.

26.

Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.

Nishijima TF, Muss HB, Shachar SS, Moschos SJ.

Cancer Treat Rev. 2016 Apr;45:30-7. doi: 10.1016/j.ctrv.2016.02.006. Epub 2016 Mar 2. Review.

PMID:
26946217
27.

Ebola Check: Delivering molecular diagnostics at the point of need.

Moschos SA.

Hell J Nucl Med. 2015 Sep-Dec;18 Suppl 1:144.

PMID:
26665227
28.

Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.

Ivanova A, Paul B, Marchenko O, Song G, Patel N, Moschos SJ.

J Biopharm Stat. 2016;26(1):141-9. doi: 10.1080/10543406.2015.1092030. Review.

29.

Introducing EbolaCheck: potential for point-of-need infectious disease diagnosis.

Moschos SA.

Expert Rev Mol Diagn. 2015;15(10):1237-40. doi: 10.1586/14737159.2015.1084228. Epub 2015 Sep 1.

PMID:
26327281
30.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.

Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.

PMID:
26115796
31.

Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC.

Zhao X, Wang A, Walter V, Patel NM, Eberhard DA, Hayward MC, Salazar AH, Jo H, Soloway MG, Wilkerson MD, Parker JS, Yin X, Zhang G, Siegel MB, Rosson GB, Earp HS 3rd, Sharpless NE, Gulley ML, Weck KE, Hayes DN, Moschos SJ.

PLoS One. 2015 Jun 15;10(6):e0129280. doi: 10.1371/journal.pone.0129280. eCollection 2015.

32.

IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.

Carson CC, Moschos SJ, Edmiston SN, Darr DB, Nikolaishvili-Feinberg N, Groben PA, Zhou X, Kuan PF, Pandey S, Chan KT, Jordan JL, Hao H, Frank JS, Hopkinson DA, Gibbs DC, Alldredge VD, Parrish E, Hanna SC, Berkowitz P, Rubenstein DS, Miller CR, Bear JE, Ollila DW, Sharpless NE, Conway K, Thomas NE.

Clin Cancer Res. 2015 May 1;21(9):2167-76. doi: 10.1158/1078-0432.CCR-14-1826.

33.

Targeted therapies in melanoma.

Moschos SJ, Pinnamaneni R.

Surg Oncol Clin N Am. 2015 Apr;24(2):347-58. doi: 10.1016/j.soc.2014.12.011. Epub 2015 Jan 24. Review.

34.

Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.

Wesa AK, Mandic M, Taylor JL, Moschos S, Kirkwood JM, Kwok WW, Finke JH, Storkus WJ.

Front Oncol. 2014 Sep 29;4:266. doi: 10.3389/fonc.2014.00266. eCollection 2014.

35.

DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features.

Thomas NE, Slater NA, Edmiston SN, Zhou X, Kuan PF, Groben PA, Carson CC, Hao H, Parrish E, Moschos SJ, Berwick M, Ollila DW, Conway K.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1097-105. doi: 10.1111/pcmr.12289. Epub 2014 Jul 14.

36.

Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.

Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, Burd CE, Thomas NE, Chiang DY, Liu W, Eberhard DA, Ollila D, Grilley-Olson J, Moschos S, Neil Hayes D, Sharpless NE.

Pigment Cell Melanoma Res. 2014 Jul;27(4):653-63. doi: 10.1111/pcmr.12238. Epub 2014 Apr 7.

37.

Deep Sequencing Insights in Therapeutic shRNA Processing and siRNA Target Cleavage Precision.

Denise H, Moschos SA, Sidders B, Burden F, Perkins H, Carter N, Stroud T, Kennedy M, Fancy SA, Lapthorn C, Lavender H, Kinloch R, Suhy D, Corbau R.

Mol Ther Nucleic Acids. 2014 Feb 4;3:e145. doi: 10.1038/mtna.2013.73.

38.

Induction of Gsk3β-β-TrCP interaction is required for late phase stabilization of β-catenin in canonical Wnt signaling.

Gao C, Chen G, Romero G, Moschos S, Xu X, Hu J.

J Biol Chem. 2014 Mar 7;289(10):7099-108. doi: 10.1074/jbc.M113.532606. Epub 2014 Jan 22.

39.

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM.

Cancer Res. 2014 Feb 15;74(4):1045-55. doi: 10.1158/0008-5472.CAN-13-2908. Epub 2013 Dec 16.

40.

Pathologic and gene expression features of metastatic melanomas to the brain.

Hamilton R, Krauze M, Romkes M, Omolo B, Konstantinopoulos P, Reinhart T, Harasymczuk M, Wang Y, Lin Y, Ferrone S, Whiteside T, Bortoluzzi S, Werley J, Nukui T, Fallert-Junecko B, Kondziolka D, Ibrahim J, Becker D, Kirkwood J, Moschos S.

Cancer. 2013 Aug 1;119(15):2737-46. doi: 10.1002/cncr.28029. Epub 2013 May 21.

41.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Liu J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK.

J Clin Invest. 2013 May;123(5):2257-67. doi: 10.1172/JCI67816. Epub 2013 Apr 15.

42.

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.

J Clin Oncol. 2013 May 10;31(14):1767-74. doi: 10.1200/JCO.2012.44.7888. Epub 2013 Apr 8.

PMID:
23569304
43.

HIF1α and HIF2α independently activate SRC to promote melanoma metastases.

Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET 3rd, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY.

J Clin Invest. 2013 May;123(5):2078-93. doi: 10.1172/JCI66715. Epub 2013 Apr 8.

44.

Historical review of melanoma treatment and outcomes.

Lee C, Collichio F, Ollila D, Moschos S.

Clin Dermatol. 2013 Mar-Apr;31(2):141-7. doi: 10.1016/j.clindermatol.2012.08.015. Review.

PMID:
23438377
45.

Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.

Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, Lin Y, Christner S, Kirkwood JM.

Ann Oncol. 2013 Apr;24(4):1112-9. doi: 10.1093/annonc/mds591. Epub 2012 Nov 21.

46.

Genomic biomarkers for patient selection and stratification: the cancer paradigm.

Moschos SA.

Bioanalysis. 2012 Oct;4(20):2499-511. doi: 10.4155/bio.12.241. Review.

PMID:
23157358
47.

A 61 year diabetic man with methicillin-sensitive Staphylococcus aureus septic arthritis and acute renal failure: a case of IgA-dominant postinfectious glomerulonephritis.

Erqou S, Kamat N, Moschos S, Im A, Bastacky S.

Nephrology (Carlton). 2012 Nov;17(8):780-1. doi: 10.1111/j.1440-1797.2012.01602.x. No abstract available.

PMID:
23107126
48.

Importance of glycolysis and oxidative phosphorylation in advanced melanoma.

Ho J, de Moura MB, Lin Y, Vincent G, Thorne S, Duncan LM, Hui-Min L, Kirkwood JM, Becker D, Van Houten B, Moschos SJ.

Mol Cancer. 2012 Oct 9;11:76. doi: 10.1186/1476-4598-11-76.

49.

Mitochondrial respiration--an important therapeutic target in melanoma.

Barbi de Moura M, Vincent G, Fayewicz SL, Bateman NW, Hood BL, Sun M, Suhan J, Duensing S, Yin Y, Sander C, Kirkwood JM, Becker D, Conrads TP, Van Houten B, Moschos SJ.

PLoS One. 2012;7(8):e40690. doi: 10.1371/journal.pone.0040690. Epub 2012 Aug 17.

50.

Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model.

Suhy DA, Kao SC, Mao T, Whiteley L, Denise H, Souberbielle B, Burdick AD, Hayes K, Wright JF, Lavender H, Roelvink P, Kolykhalov A, Brady K, Moschos SA, Hauck B, Zelenaia O, Zhou S, Scribner C, High KA, Renison SH, Corbau R.

Mol Ther. 2012 Sep;20(9):1737-49. doi: 10.1038/mt.2012.119. Epub 2012 Jun 26.

Supplemental Content

Loading ...
Support Center